Incidentally, the effects of ACE inhibitors and angiotensin receptor blockers on ACE2-related viral contagion and virulence modulation have not been clearly established; the current practical recommendation for patients with COVID-19 is to continue to take them (2, 4, 5, 17, 21). This evidence concerns the gene ACE2 and COVID-19.